TAG Fiercely Condemns the New Administration’s War on Science
Treatment Action Group (TAG) is disgusted and appalled by the new presidential administration’s flagrant attack on science.
This is used for Pipeline or other output lists that are grouped by project area. Name will NOT output.
Treatment Action Group (TAG) is disgusted and appalled by the new presidential administration’s flagrant attack on science.
The new U.S. presidential administration has issued several executive orders, which use pseudo-scientific claims to deny the existence of transgender and non-binary people.
Treatment Action Group (TAG) is appalled by President Donald Trump’s executive order Monday signaling the United States will be withdrawing from the World Health Organization (WHO).
Treatment Action Group’s (TAG) most important fundraising event of the year is the Research in Action Awards, which honor the best and brightest activists, researchers, leaders, and scientists whose work has been integral in ending HIV, tuberculosis (TB), and hepatitis C (HCV).
Treatment Action Group (TAG) supports the World Health Organization (WHO) in declaring the renewed outbreak of mpox a public health emergency of international concern.
Treatment Action Group (TAG) elected three new members to its Board of Directors in May 2024. Board President Ivy Kwan Arce said, "TAG is reinvigorating its Board in alignment with our vision, mission, and values.
Treatment Action Group (TAG) is pleased to present the exhibition “35 Years of Art to End AIDS” at Melissa Morgan Fine Art in Palm Desert, CA. The exhibition features selected works from TAG’s Limited Art Editions Collection and will run from March 17 through April 7.
Treatment Action Group (TAG) is honored that acclaimed American Artist Glenn Ligon has created and donated a Limited Art Edition entitled Black Rage (back cover) in an edition of 100 prints (and 20 A/Ps) especially for TAG.
June 2013 2013 HIV pipeline executive summary The 2013 HIV pipeline comprises adult and pediatric antiretroviral therapy (ART) development and dose-optimization research as well as antiretroviral preventive technologies, research toward a cure, and immune-based and gene therapies. Adult and pediatric…
June 2013 By Polly Clayden and Mark Harrington This chapter will discuss how to get the best drugs to the most people as quickly as possible; this requires that the compounds and combination products be: Discovered and developed in a…